Ignota Labs
Category: AI in Healthcare
Ignota Labs uses its SAFEPATH platform to identify and rescue promising drug candidates that failed clinical trials due to safety concerns. Ignota Labs was founded in 2021. The company is led by Sam Windsor. Based in Cambridge Science Park, Cambridge, UK. Team size: N/A. Total funding raised: $7.9 million. Latest round: $6.9 million seed funding. Key investors include Montage Ventures, AIX Ventures, Modi Ventures, Blue Wire Capital, Gaingels.
- Founded
- 2021
- Headquarters
- Cambridge Science Park, Cambridge, UK
- Team size
- N/A
- Total funding
- $7.9 million
Value proposition
The SAFEPATH platform offers a data-driven approach to detect and resolve drug toxicity issues, enabling the re-engineering and revival of therapies that would otherwise be abandoned.
Products and solutions
SAFEPATH platform, First-in-class metabolic health drug for post-menopausal women (early-stage)
Unique value
Combines deep learning, cheminformatics, and bioinformatics to uncover molecular mechanisms behind drug toxicity and rescue failed drugs.
Target customer
Pharmaceutical companies looking to revitalize shelved drug assets and patients who may benefit from revived therapies
Industries served
Biotechnology, Pharmaceuticals, Healthcare
Technology advantage
Its proprietary SAFEPATH platform minimizes reliance on traditional trial-and-error methods by employing a data-driven approach, streamlining drug development.
How they differentiate
Focused on rescuing failed drug candidates by addressing safety concerns using advanced AI methods, unlike competitors solely discovering new compounds.
Main competitors
LabGenius, BenevolentAI, Large pharmaceutical companies with internal AI initiatives
Key partnerships
Montage Ventures, AIX Ventures, Modi Ventures, Blue Wire Capital, Gaingels
Major milestones
Relocated to Cambridge Science Park Won the OxbridgeAI Challenge Secured significant seed funding Published research validating its AI-driven approach
Growth metrics
Has in-licensed its first drug asset and is expanding its pipeline; detailed metrics are not publicly disclosed.
Market positioning
Emerging leader in AI-driven drug repurposing and rescue solutions.
Geographic focus
Primarily based in the UK with a growing global reach in the pharmaceutical market
Patents and IP
No specific patent numbers disclosed; intellectual property is primarily based on the SAFEPATH platform and its underlying AI models.
About Sam Windsor
Sam Windsor is the Co-Founder and CEO of Ignota Labs, bringing a wealth of experience from the healthcare and technology sectors. His background includes consulting for major firms and a strong academic foundation with an MBA from INSEAD. He has been instrumental in shaping the company's strategy and securing early partnerships.
Official website: https://www.ignotalabs.ai